Merck (MRK) Income from Continuing Operations (2009 - 2026)
Merck (MRK) reported Income from Continuing Operations of 4209000000.0 for Q1 2026, down 182.77% year-over-year from 5085000000.0 in Q1 2025, and down 242.1% quarter-over-quarter from 2962000000.0 in Q4 2025.
Merck (MRK) Income from Continuing Operations (2009 - 2026) Analysis & Trends
Merck (MRK) has 18 years of Income from Continuing Operations data on file, last reported at 4209000000.0 in Q1 2026.
- Income from Continuing Operations for Q1 2026 came in at 4209000000.0, down 182.77% year-over-year; the trailing twelve-month figure through Mar 2026 was 8968000000.0 (down 48.61% YoY), and the FY2025 annual result was 18263000000.0, up 6.6% from the prior year.
- Income from Continuing Operations slipped to 4209000000.0 in Q1 2026 per MRK's latest filing, from 2962000000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 5787000000.0 in Q3 2025 and troughed at 5937000000.0 in Q2 2023.
- A 5-year average of 2713235294.12 and a median of 3744000000.0 in 2024 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2023 and 2024: Income from Continuing Operations slumped 250.34% in 2023, then soared 405.38% in 2024.
- A 5-year view of Income from Continuing Operations shows it stood at 3018000000.0 in 2022, then slumped by 140.62% to 1226000000.0 in 2023, then soared by 405.38% to 3744000000.0 in 2024, then decreased by 20.89% to 2962000000.0 in 2025, then plunged by 242.1% to 4209000000.0 in 2026.
- Business Quant data shows MRK's Income from Continuing Operations at 4209000000.0 in Q1 2026, 2962000000.0 in Q4 2025, and 5787000000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | 3.30 Bn |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | 7.40 Bn |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | 5.24 Bn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | 697.00 Mn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | -4.21 Bn |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | 1.82 Bn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | 2.02 Bn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | 2.71 Bn |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | 2.68 Bn |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.21 Bn |
| Dec 31, 2025 | 2.96 Bn |
| Sep 30, 2025 | 5.79 Bn |
| Jun 30, 2025 | 4.43 Bn |
| Mar 31, 2025 | 5.09 Bn |
| Dec 31, 2024 | 3.74 Bn |
| Sep 30, 2024 | 3.16 Bn |
| Jun 30, 2024 | 5.46 Bn |
| Mar 31, 2024 | 4.77 Bn |
| Dec 31, 2023 | -1.23 Bn |
| Sep 30, 2023 | 4.75 Bn |
| Jun 30, 2023 | -5.94 Bn |
| Mar 31, 2023 | 2.83 Bn |
| Dec 31, 2022 | 3.02 Bn |
| Sep 30, 2022 | 3.25 Bn |
| Jun 30, 2022 | 3.95 Bn |
| Mar 31, 2022 | 4.31 Bn |
| Dec 31, 2021 | 3.82 Bn |
| Sep 30, 2021 | 4.57 Bn |
| Jun 30, 2021 | 1.21 Bn |